12.25
+0.38(+3.20%)
Currency In USD
| Previous Close | 11.87 |
| Open | 11.83 |
| Day High | 12.29 |
| Day Low | 11.76 |
| 52-Week High | 18.07 |
| 52-Week Low | 11.13 |
| Volume | 924,314 |
| Average Volume | 1.12M |
| Market Cap | 1.24B |
| PE | -12.63 |
| EPS | -0.97 |
| Moving Average 50 Days | 13.4 |
| Moving Average 200 Days | 14.17 |
| Change | 0.38 |
If you invested $1000 in Day One Biopharmaceuticals, Inc. (DAWN) since IPO date, it would be worth $521.28 as of January 16, 2025 at a share price of $12.25. Whereas If you bought $1000 worth of Day One Biopharmaceuticals, Inc. (DAWN) shares 3 years ago, it would be worth $859.05 as of January 16, 2025 at a share price of $12.25.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities
GlobeNewswire Inc.
Jan 13, 2025 1:00 PM GMT
Preliminary 2024 OJEMDA™ (tovorafenib) net product revenue of approximately $57.2 million (unaudited) First dose cohort cleared in Phase 1a/b clinical trial of DAY301 (PTK7-targeted ADC) Ended 2024 with approximately $531.7 million in cash, cash equi
Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 17, 2024 1:30 PM GMT
BRISBANE, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
GlobeNewswire Inc.
Nov 20, 2024 9:30 PM GMT
Dr. Blackman’s departure planned for end of 2024 Company’s search for a new Head of R&D is ongoing BRISBANE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical